KTTA Latest Press Releases

-- April 20, 2026 --

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Globe Newswire 7:01 AM

-- April 1, 2026 --

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity Globe Newswire 7:01 AM

-- February 17, 2026 --

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 7:01 AM

-- January 13, 2026 --

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines Globe Newswire 7:01 AM

-- December 2, 2025 --

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock Globe Newswire 7:00 AM

-- November 28, 2025 --

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock Globe Newswire 9:20 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software